Dealing with regulatory bodies can be terrifying, especially for a startup facing a recall. The key is to present objective facts, demonstrate a rigorous process, and make decisions that protect the product and patient. This builds trust and ensures long-term viability.

Instead of immediately releasing functional data to satisfy investors and social media, Solid Biosciences is strategically withholding it. The company will first share the analysis with the FDA to align on an accelerated approval pathway, believing this professional courtesy builds a stronger regulatory relationship and improves the long-term outcome.

Augurex's CEO advises engaging the FDA early. The agency's crucial feedback was to use "mechanical back pain" patients as the control group, not just healthy individuals. This guidance forced the company to generate data that directly proved its key value proposition: differentiating inflammatory from mechanical pain.

The CEO revealed a capital-efficient strategy: combining data from both its severe asthma and nasal polyps Phase 2 trials to inform a unified Phase 3 development plan. This allows the company to engage with regulators for both indications simultaneously, accelerating development and conserving resources by leveraging a single robust dataset across programs.

Bio is creating a formal system for biotech companies to report challenges with the FDA. Bio will synthesize this feedback monthly and present it directly to FDA leadership, creating a novel channel to elevate systemic issues and improve accountability.

A key employee at Jared Bauer's first company taught him that agencies like the FDA are not enemies. By understanding their goal is to protect patients, he learned to partner with them and proactively address their concerns, a mindset he found highly effective.

Instead of passively waiting for clarity, Almac aggregated common sponsor concerns about new UK trial regulations and presented them to the MHRA. This proactive engagement was "unprecedented" and resulted in the regulator rapidly updating its guidance, demonstrating that a collaborative approach can shape and accelerate regulatory clarification.

For every formal weekly meeting with the core evaluation group, an enterprise rep should have at least three to four one-on-one conversations with individual stakeholders. This high ratio of offline, individual alignment to formal group sessions is critical for navigating politics and driving consensus in complex sales cycles.

When building a product with multiple funding customers and stakeholders, use a structured workshop process. Present a proposal, clarify questions, gather reactions, amend, and then vote. This formal process forces alignment and achieves consensus, even with competing interests.